Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including ...

Abecma is a medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to ...

Trade Name: Abecma. Active Substances: Idecabtagene, Vicleucel. Dosage Form: Dispersion for infusion. Licence Holder: Bristol-Myers Squibb Pharmaceuticals uc.

Abecma's Summary of Product Characteristics (SmPC) and the associated package leaflet (PL) give essential information to healthcare professionals (HCPs) and ...

19 авг. 2021 г. · Abecma is the first and only CAR T cell therapy approved that is directed to recognize and bind to BCMA, a protein that is nearly universally expressed on ...

Company: Bristol-Myers Squibb Pharma EEIG. Status: New. Active Ingredient(s):. idecabtagene vicleucel. *Additional information is available within the SPC ... Не найдено: smpc | Нужно включить: smpc

12 июн. 2024 г. · ABECMA is the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of ... Не найдено: smpc | Нужно включить: smpc

Summary of product characteristics (SmPC), labelling and package leaflet (PL), download. Link to the European Medicines Agency's (EMA) product information ...

Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after ...

This is an overview of all Bristol Myers Squibb medicines, both reimbursed and non-reimbursed. ABECMA (idecabtagene vicleucel).